Alzamend Neuro (ALZN) News Today → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free ALZN Stock Alerts $0.53 -0.03 (-5.38%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAlzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slidemsn.com - May 7 at 7:11 PMAlzamend Neuro Announces Termination of At-the-Market Equity Offering Programfinance.yahoo.com - May 7 at 8:19 AMAlzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buyingmsn.com - April 24 at 9:21 AMAlzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42msn.com - April 17 at 10:47 AMALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024msn.com - March 26 at 6:50 AMAlzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50msn.com - February 24 at 7:51 PMMaxim gets more bearish on Alzamend Neuro, downgrades sharesrealmoney.thestreet.com - February 13 at 2:46 PMAlzamend Neuro Risks Nasdaq Delisting Over Price Deficiencymsn.com - February 3 at 10:31 AMBuy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market Potentialmarkets.businessinsider.com - December 19 at 6:51 PMALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024msn.com - December 18 at 12:33 PMALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024msn.com - December 18 at 12:33 PMAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patientsfinance.yahoo.com - December 11 at 11:26 AMEXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Yearfinance.yahoo.com - December 11 at 11:26 AMAlzamend Neuro Gets FDA Approval for Trial of Depression Treatmentmarketwatch.com - November 20 at 10:27 AMEXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Studymsn.com - November 20 at 10:27 AMAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patientsfinance.yahoo.com - November 20 at 10:27 AMAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirementfinance.yahoo.com - November 16 at 10:02 AMEXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidatemsn.com - November 13 at 8:52 AMAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001finance.yahoo.com - November 13 at 8:52 AMAlzamend Neuro (ALZN) Price Target Increased by 1306.25% to 57.38msn.com - November 2 at 12:25 AMWhy Alzamend Neuro (ALZN) Stock Is Nosediving Todaybenzinga.com - October 30 at 3:48 PMAlzamend Neuro Announces Reverse Stock Splitfinance.yahoo.com - October 30 at 9:47 AMAlzamend Neuro, Inc. (9ZT0.F)finance.yahoo.com - October 25 at 7:25 PMAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001businesswire.com - October 23 at 12:38 PMEXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disordermsn.com - October 2 at 8:54 AMAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patientsfinance.yahoo.com - October 2 at 8:54 AMAlzamend Neuro CFO Katzoff buys 53K sharesseekingalpha.com - September 27 at 3:26 PMRep. Jennifer Wexton Will Not Run for Re-Election After Rare Neurological Disorder Diagnosisyahoo.com - September 26 at 6:09 PMAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirementfinance.yahoo.com - September 22 at 12:54 PMEXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disordermsn.com - August 30 at 9:31 AMAlzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patientsfinance.yahoo.com - August 30 at 9:31 AMBenzinga Neurobenzinga.com - August 25 at 6:57 PMWe're A Little Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Ratefinance.yahoo.com - August 24 at 4:32 PMMaxim Group Reaffirms Their Buy Rating on Alzamend Neuro (ALZN)markets.businessinsider.com - June 28 at 10:07 AMAlzamend Neuro Inc Ordinary Sharesmorningstar.com - June 24 at 10:33 AMAlzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001finance.yahoo.com - June 22 at 12:49 PMEXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Studybenzinga.com - June 22 at 7:49 AMAlzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Group’s Virtual Healthcare Conferencefinance.yahoo.com - June 13 at 9:11 AMAlzamend Neuro Stock (NASDAQ:ALZN), Dividendsbenzinga.com - April 14 at 7:59 AMMaxim Group Initiates Coverage of Alzamend Neuro (ALZN) with Buy Recommendationmsn.com - April 12 at 6:58 PMAlzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Typefinance.yahoo.com - April 3 at 9:56 AMEXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccinefinance.yahoo.com - April 3 at 9:56 AMKILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Typefinance.yahoo.com - April 3 at 9:56 AMEXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trialfinance.yahoo.com - March 22 at 12:35 PMWe Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefullyfinance.yahoo.com - March 17 at 8:29 AMAlzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Updatefinance.yahoo.com - March 16 at 9:44 AMAlzamend Neuro Inc.barrons.com - February 21 at 12:23 AMAlzamend Neuro to Present at Sequire Biotechnology Conferencefinance.yahoo.com - January 26 at 9:47 AMAlzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trialfinance.yahoo.com - January 4 at 9:31 AMEXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementiafinance.yahoo.com - December 28 at 1:24 PM Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode May 20th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career… Click For My #1 FREE Crypto for 2024 ALZN Media Mentions By Week ALZN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALZN News Sentiment▼0.560.36▲Average Medical News Sentiment ALZN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALZN Articles This Week▼20▲ALZN Articles Average Week Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cingulate News Today Oragenics News Today NexImmune News Today Synaptogenix News Today Lipella Pharmaceuticals News Today China Pharma News Today Petros Pharmaceuticals News Today Exicure News Today Artelo Biosciences News Today Bright Minds Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALZN) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetry348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
